Published ahead of print on March 24, 2011
doi: 10.3174/ajnr.A2472

American Journal of Neuroradiology 32:E71-E72, April 2011
© 2011 American Society of Neuroradiology

R.C. Quah^a
aDepartment of Nuclear Medicine
Singapore General Hospital
Singapore

Paragangliomas of the neck are rare somatostatin receptor-expressingneuroendocrine tumors. Somatostatin-receptor scintigraphy is useful in diagnosing and staging these tumors, as well as assessing residual or recurrent disease posttreatment. We describe the gallium 68 DOTA, _DPhe¹, Tyr³-octreotate positron-emission tomography-CT (⁶⁸Ga-DOTATATE PET-CT) findings of bilateral neck paragangliomas as seen in the following patient.

A previously healthy 40-year-old woman presented with asymmetricsensorineural hearing loss, right more than left, which was confirmed on an audiogram. There was no other neurologic deficit. MR imaging of the internal auditory meati did not reveal any abnormality at the cerebellopontine angles or internal auditory canals; however, a left carotid space mass was partially visualized. A dedicated MR image of the neck revealed avidly enhancing lobulated masses within bilateral carotid spaces (Figs 1 and 2 A). The right neck mass extended from the level of the carotid bifurcation to the level of the nasopharynx and splayed the right internal and external carotid arteries. The left neck mass extended from the level of the oropharynx to the left jugular foramen, splaying the left internal jugular vein and internal carotid artery. ⁶⁸Ga-DOTATATE PET-CT demonstrated intense tracer uptake within the bilateral carotid space masses (Fig 2B). There was no other abnormal focus of increased tracer uptake in the rest of the body to suggest the presence of metastasis. These imaging findings confirmed a right carotid body tumor and a left glomus vagale. Biochemical screening revealed elevated urine norepinephrine (622 nmol/day; normal, 89–473 nmol/day) and normetanephrine (2895 nmol/day; normal, 600-1900 nmol/day) levels. The patient opted for and is scheduled to undergo radiation therapy.

DOTATATE is a somatostatin analog, which can be radio-labeled with ⁶⁸Ga. ⁶⁸Ga is a positron emitter with a half-life of 68minutes, produced by elution from ⁶⁸Ge in a ⁶⁸Ga generator. ⁶⁸Ga-DOTATATE shows a high affinity for somatostatin type 2receptors (SSR-2), is rapidly excreted from nontarget sites, and offers good target-to-nontarget imaging properties. Compared with indium 111-diethylene triamine pentaacetic acid-octreotide, ⁶⁸Ga-DOTATATE demonstrates better sensitivity for neuroendocrine tumors¹ and is useful for the diagnosis of small tumors and evaluation of disease response following therapy.² The mainstay of treatment for paragangliomas in the head and neck region has been surgical resection, preoperative embolization, and/or external beam radiation therapy, though a role for stereotactic radiosurgery is emerging.³There is also a promising role for peptide-receptor radionuclide therapy, where the somatostatin analog DOTATATE is radio-labeled with the β emitter lutetium 177 (¹⁷⁷Lu) to deliver highly targeted doses to tumors expressing the SSR-2, with low doses to the normal organs.⁴

Our case highlights the intense and specific tracer uptake of ⁶⁸Ga-DOTATATE in paragangliomas of the neck, which will be useful if findings on other imaging modalities are equivocal. There is also a promising role for using ¹⁷⁷Lu-DOTATATE for highly targeted radionuclide therapy of these tumors.

References

1. Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010;51:875–82.Epub 2010 May 19[Abstract/Free Full Text]
2. Haug AR, Auernhammer CJ, Wängler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well differentiated neuroendocrine tumors. J Nucl Med 2010;51:1349–56[Abstract/Free Full Text]
3. Kupferman ME, Hanna EY. Paragangliomas of the head and neck. Curr Oncol Rep 2008;10:156–61[CrossRef][Medline]
4. Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 2010;14:247–51